Briefing: Leading Pharma Companies to Watch in Today's Market Session

    Briefing: Leading Pharma Companies to Watch in Today's Market Session

  PR Newswire

  CORAL SPRINGS, Florida, February 5, 2013

CORAL SPRINGS, Florida, February 5, 2013 /PRNewswire/ -- "Active Health Stocks to Watch" for today: Crown
Marketing Pharmaceuticals ( CWNM ), Keryx Biopharmaceuticals Inc. (NASDAQ:
KERX ), Rexahn Pharmaceuticals, Inc. (NYSE: RNN ), Amarin Corporation (NASDAQ:

Headline News Summary: Crown Marketing Pharmaceuticals ( CWNM ) announced
today that Patents for its Controlled Drug Delivery Technology (CDDT) have
been approved and registered in Norway. Crown is continuing to secure its
worldwide patent rights as it pursues novel applications of its drug delivery
technology. Crown's cost-effective application of controlled delivery
technologies plays a major role in the expansion of the pharmaceutical, OTC
and nutraceuticals industry through its ability to improve on the performance
of immediate release products in a manner tangible to manufacturers and
consumers. The objective of intelligent drug delivery design amounts to
maximizing the percent of the time drug plasma levels are within the
therapeutic range and avoiding patient exposure to potentially toxic (High) or
sub-therapeutic (Low) levels. For more details regarding Crown's CDDT
applications, go to 

Another major pharmaceutical company catching attention in the markets today
was Keryx Biopharmaceuticals Inc. (NASDAQ: KERX ) as questions arose
regarding the company's ability to convince the FDA to grant New Chemical
Entity status to KERX's experimental iron-based phosphate binder Zerenex.
Keryx intends to seek U.S. and European approval for Zerenex, which would be
used to lower blood levels of phosphorous in patients undergoing kidney
dialysis. Zerenex may have a commercial advantage over other so-called
phosphate binders because its iron-based core appears to reduce the need for
intravenous iron and expensive anemia-boosting drugs like Amgen Inc.'s
(NASDAQ: AMGN ) Epogen. Epogen is used to treat a lower than normal number of
red blood cells (anemia) caused by chronic kidney disease in patients on
dialysis to lessen the need for red blood cell transfusions.

In other patent related news, Amarin Corporation (NASDAQ: AMRN ) announced
recently that the United States Patent and Trademark Office (USPTO) has
published notification of a Notice of Allowance for Amarin's U.S. Patent
Application Serial Number 13/272,520 titled "Compositions and Methods for
Lowering Triglycerides." This application includes claims intended to protect
the proposed Vascepa (icosapent ethyl) indication based on Amarin's Phase 3
ANCHOR clinical trial results. Amarin is on track to file a Supplemental New
Drug Application for the Vascepa ANCHOR indication with the U.S. Food and Drug
Administration (FDA) by the end of February 2013, and expects an FDA action
date on the application before the end of 2013. AMRN closed up ever so
slightly yesterday at $8.52 per share on over 3.45Million shares. Rexahn
Pharmaceuticals, Inc. (NYSE: RNN ) closed up 12% on 6.76Million shares traded.
RNN is a clinical stage pharmaceutical company dedicated to developing and
commercializing first in class and market leading therapeutics for cancer and
other unmet medical needs. Rexahn currently has three key oncology drug
candidates in clinical stages, Archexin(R), RX-3117, and RX-5902 and a robust
pipeline of preclinical compounds to treat multiple cancers. Rexahn also
operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery
platforms.   is leading provider of third party publishing &
news dissemination services. If you would like more information regarding our
news coverage solutions, please visit  
for more details. 

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities.  The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information: Company:  FN Media Group, LLC Contact email: U.S. Phone: +1-(954)345-0611 URL:
Press spacebar to pause and continue. Press esc to stop.